The goal of this observational study is to learn about toxicities and cosmetic outcomes in breast cancer patients treated with hypofractionated radiotherapy. The main question it aims to answer are: * Changes in breast skin * Factors related to breast skin changes * Patient-reported outcomes * Cosmetic outcomes Participants will be assessed by multi-dimensional methods before and after radiotherapy: * Photographs * Fibrometer * Questionnaires (BREAST-Q) * CTCAE version 4.03 evaluated by treating physicians
Study Type
OBSERVATIONAL
Enrollment
500
Both 3-week and 1-week hypofractioanted radiation therapy are allowed. (simultaneous or sequential tumor bed boost is allowed.) A 3-week regimen includes 42.4 Gy in 16 fractions. A 1-week regimen includes 26 Gy in 5 fractions or 28.5 Gy in 3 fractions, 30 Gy in 5 fractions.
Samsung Medical Center
Seoul, South Korea
RECRUITINGChange of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: After 2-3 weeks after the start of radiation therapy (During radiation therapy)
Change of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: 2-3 weeks after the completion of radiation therapy
Change of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: 6 months after radiation therapy
Change of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: 1 year after radiation therapy
Change of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: 2 year after radiation therapy
Change of cosmesis from baseline
Evaluated by two blinded independent physicians based on photographs
Time frame: 5 year after radiation therapy
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: After 2-3 weeks after the start of radiation therapy (During radiation therapy)
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: 2-3 weeks after the completion of radiation therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: 6 months after radiation therapy
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: 1 year after radiation therapy
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: 2 year after radiation therapy
Change of fibrosis from baseline
Evaluated using fibrometer measuring both breast
Time frame: 5 year after radiation therapy
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: After 2-3 weeks after the start of radiation therapy (During radiation therapy)
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: 2-3 weeks after the completion of radiation therapy
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: 6 months after radiation therapy
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: 1 year after radiation therapy
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: 2 year after radiation therapy
Change of patient-reported outcome from baseline
BREAST-Q questionnaire is used to evaluate patient-reported outcome.
Time frame: 5 year after radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: After 2-3 weeks after the start of radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: 2-3 weeks after the completion of radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: 6 months after radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: 1 year after radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: 2 year after radiation therapy
Physician assessed toxicity
CTCAE version 4.03 is used to evaluate physician-assessed toxicities.
Time frame: 5 year after radiation therapy